Pharsight

1. List of Doryx drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6958161	MAYNE PHARMA	Modified release coated drug preparation	Dec, 2022 (5 months ago)
US8715724	MAYNE PHARMA	Tabletting process	Feb, 2028 (4 years from now)
US9295652	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (11 years from now)
US9511031	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (11 years from now)
US9446057	MAYNE PHARMA	Controlled release doxycycline	Dec, 2034 (11 years from now)

Do you want to check out DORYX patents from before 2022?

Market Authorisation Date: 06 May, 2005

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
75 mg and 100 mg	05 Feb, 2009	1	28 Dec, 2010	15 Dec, 2022	Eligible
150 mg	19 Dec, 2008	1		15 Dec, 2022	Extinguished
200 mg	19 May, 2014	1	19 May, 2016	15 Dec, 2022	Eligible
80 mg	01 Jul, 2015	1	29 Apr, 2016	15 Dec, 2022	Eligible
50 mg	05 Nov, 2015	1	23 May, 2016	03 Feb, 2028	Eligible
60 mg and 120 mg	28 Sep, 2017	1		23 Dec, 2034

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 60MG BASE	TABLET, DELAYED RELEASE;ORAL	Discontinued
EQ 120MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription